Medigus Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
11/30/2022 - 09:10 AM
Tel Aviv, Israel, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ADSs to maintain a minimum bid price of $1.00 per ADS.
The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ADSs was at $1.00 per ADS or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technology company focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce and electric vehicle markets. Medigus' affiliations in the medical solutions arena include ownership in Polyrizon Ltd. and ownership in industry 4.0 company, ScoutCam Inc. The Company’s affiliates in digital commerce include Gix Internet Ltd., Jeffs' Brands Ltd. and Eventer Technologies Ltd. In the electric vehicle market, Charging Robotics Ltd. and Revoltz Ltd. are also part of the Company’s portfolio of technology solution providers. To learn more about Medigus’ advanced technologies, please visit http://www.medigus.com/ .
Company Contact: Tali Dinar Chief Financial Officer +972-8-6466-880 ir@medigus.com
Investor Relations Contact: Dave Gentry RedChip Companies Inc. 1-800-RED-CHIP (733-2447) Or 407-491-4498MDGS@redchip.com
MDGS Rankings
N/A Ranked by Stock Gains
MDGS Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
Israel
City
Pob 3030
About MDGS
medical device company focused on innovative endoscopic procedures and devices. medigus developed an entire endoscopic system for intraluminal treatment of gerd (gastroesophageal reflux disease), one of the most common chronic diseases in the western world. the endoscopic system for the treatment of gerd - the srs - combines a miniaturized video camera, a surgical stapler and ultrasonic sights for alignment in a single instrument. the srs system and its unique flexible endoscope allows gastroenterologists and surgeons to perform endoluminally a true partial anterior fundoplication, thereby revolutionizing the treatment of gerd by eliminating the need for open or laparoscopic surgery - the current standard practice for treating severe gerd. shifting the gerd treatment from surgery to an endoluminal procedure, without opening the abdominal cavity, is a revolution. in addition, medigus designs and manufactures endoscopy systems for partner companies based on its proprietary technologies,